TrialSignal
Clinical trial intelligence report
Clinical Study of CD123 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/refractory Acute Myeloid Leukemia (AML)or Blastic Plasmacytoid Dendritic Cell Neoplasm(BPDCN)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT06690827
Status
RECRUITING
Phase
Phase 1
Sponsor
Chongqing Precision Biotech Co., Ltd
Executive brief
Investment-Ready Snapshot
Chongqing Precision Biotech Co., Ltd is advancing a novel CAR-NK cell therapy targeting CD123 for the treatment of relapsed/refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). The trial is currently recruiting and aims to establish safety and efficacy, with potential implications for a significant market given the high unmet need in these malignancies. The competitive landscape includes other CAR-T and NK cell therapies, but the specificity for CD123 may provide a differentiated therapeutic profile. Successful outcomes could position Chongqing Precision Biotech favorably for partnerships or acquisition opportunities in the oncology space.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06690827
Indication
AML (Acute Myeloid Leukemia)
Modality
small molecule
Target
CD123 (Cluster of Differentiation 123), a cell surface marker expressed on certain hematological malignancies, targeted by Chimeric Antigen Receptor Natural Killer (CAR-NK) cells.
Intervention
Anti-CD123 CAR NK cells
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.